Skip to main content

Table 1 Baseline characteristics of study participants described for primary and secondary outcome measures.

From: Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

  Placebo
(n = 6)
Ascorbic acid
(n = 5)
Male/Female (numbers) 2/4 3/2
Age (years)b 16 (13-24) 19 (14-24)
Median nerve MNCV (m/s)a 17.9 (6.0) 17.2 (1.7)
Median nerve minimal F response latency (ms)a 83.8 (28.0)* 77.1 (10.6)
CMAP amplitude abductor pollicis brevis muscle (mV)a 3.9 (1.1) 4.0 (1.2)
Three point grip (N)a 50.9 (14.4) 73.8 (24.7)
Foot dorsiflexors (N)a 79.5 (14.0) 91.1 (26.9)
ISSb 2 (0-8) 3 (1-6)
CMTNSb 10 (7-20) 13 (7-17)
ODSSb 3 (2-4) 2 (2-4)
ALDSa 86.8 (6.5) 89.0 (0.5)
Nine hole peg test (s)a 26.3 (6.6) 23.5 (1.8)
50 m walking (s)a 31.9 (2.0) 29.2 (3.2)
  1. a Mean (standard deviation) b Median (range) * n = 5
  2. Abbreviations: ALDS = Academic Medical Centre linear disability score; CMAP = Compound muscle action potential; CMTNS = Charcot-Marie-Tooth neuropathy score; ISS = inflammatory neuropathy cause and treatment sensory sum score; MNCV = motor nerve conduction velocity; ODSS = overall disability sum score